Quizartinib use time and treatment plan

Quizartinib (Quizartinib), is a highly effectiveIItypeFLT3tyrosine kinase inhibitor, mainly used to treat adult patients with FLT3-ITDpositive acute myeloid leukemia (AML), especially those who have received at least one therapy but failed to achieve good results. Its mechanism of action is to selectively target the FLT3-ITD mutation and block the proliferation and survival of leukemia cells by inhibiting the activity of FLT3 kinase, thereby providing new treatment hope for patients.

During the use of Quizartinib, patients must follow the doctor's instructions and take the medication in strict accordance with the prescribed dosage and medication time. In general, the recommended initial dose of quizartinib is 26.5 mg once daily for two weeks, then adjusted to 53 mg once daily. However, the specific medication regimen may be individually adjusted based on factors such as the patient's age, weight, liver function status, and treatment response.

As to how long you should take quizartinib, this usually depends on the patient's specific condition and response to treatment. During each chemotherapy cycle, patients take quizartinib by mouth at about the same time every day for two weeks. After treatment, the doctor will comprehensively evaluate the patient's condition changes and treatment effects to decide whether to continue the next cycle of treatment. In addition, after chemotherapy is completed, doctors may also recommend continuing to use quizartinib as maintenance treatment to consolidate the efficacy of chemotherapy and prolong the patient's survival time.

It should be noted that treatment with Quizartinib is often a long-term process, during which patients need to be continuously monitored and evaluated by doctors to ensure the effectiveness and safety of the treatment. Patients should pay close attention to their health conditions and promptly report any abnormalities or discomfort to their doctors. At the same time, it is also very important to follow the doctor's advice and conduct regular electrocardiogram, liver function and blood routine examinations, so that possible side effects can be discovered and dealt with in time.

In general, although quizartinib, as a new type of therapy, has brought new treatment options to patients with acute myeloid leukemia, the time and method of its use need to be under the guidance of a professional medical team to ensure that patients obtain the best therapeutic effect and quality of life.

xa0

References:https://www.gov.uk/government/news/quizartinib-approved-to-treat-adult-patients-with-a-type-of-blood-cancer